Technical Analysis for MLNTQ - Melinta Therapeutics Inc

Grade Last Price % Change Price Change
grade F 0.08 -27.27% -0.0300
MLNTQ closed down 27.27 percent on Friday, April 3, 2020, on 2.01 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical MLNTQ trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
New Downtrend Bearish 0.00%
Doji - Bullish? Reversal 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -27.27%
20 DMA Support Bullish -27.27%
1,2,3 Pullback Bullish Bullish Swing Setup -27.27%
Boomer Buy Setup Bullish Swing Setup -27.27%
Older signals for MLNTQ ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Medicine Health RTT Pharmaceutical Chemical Compounds U.S. Bankruptcy Court Infection U.S. Bankruptcy Court For The District Of Delaware Antibiotic Anti Acne Preparations Anti Infectives Tetracycline Antibiotics Delafloxacin Gram Negative Infections Bacterial Infectious Diseases Baxdela Lipoglycopeptide Medical Research Council Melinta Therapeutics Skin Structure Infections Tetracycline Treatment Of Bacterial Infectious Diseases Yale University

Is MLNTQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.5
52 Week Low 0.06
Average Volume 117,192
200-Day Moving Average 0.0000
50-Day Moving Average 0.2091
20-Day Moving Average 0.1027
10-Day Moving Average 0.1080
Average True Range 0.0540
ADX 31.28
+DI 14.0611
-DI 17.2195
Chandelier Exit (Long, 3 ATRs ) 0.0180
Chandelier Exit (Short, 3 ATRs ) 0.2220
Upper Bollinger Band 0.1426
Lower Bollinger Band 0.0628
Percent B (%b) 0.22
BandWidth 77.7020
MACD Line -0.0297
MACD Signal Line -0.0382
MACD Histogram 0.0085
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1550
Resistance 3 (R3) 0.1567 0.1333 0.1425
Resistance 2 (R2) 0.1333 0.1142 0.1325 0.1383
Resistance 1 (R1) 0.1067 0.1024 0.0950 0.1050 0.1342
Pivot Point 0.0833 0.0833 0.0775 0.0825 0.0833
Support 1 (S1) 0.0567 0.0642 0.0450 0.0550 0.0258
Support 2 (S2) 0.0333 0.0524 0.0325 0.0217
Support 3 (S3) 0.0067 0.0333 0.0175
Support 4 (S4) 0.0050